ASTRAZENECA PLC
ActiveKey figures
Amounts are in USD (the currency of the accounts).
ASTRAZENECA PLC files its accounts at Companies House on paper. The figures here are for the whole group, taken from its annual financial report in the structured ESEF format (published on the FCA National Storage Mechanism, collected by filings.xbrl.org).
Ratios
2025Sector comparison
SIC 21100Where the company stands among the 1,055 active companies whose first SIC code is 21100 (Manufacture of basic pharmaceutical products).
- GE HEALTHCARE LIMITED£5.6bn
- THERMO FISHER SCIENTIFIC LIFE HOLDINGS LIMITED£1.4bn
- LRC PRODUCTS LIMITED£1bn
- SMITHKLINE BEECHAM LIMITED£940m
- DECHRA LIMITED£780.1m
- IPSEN BIOPHARM LIMITED£588.2m
- ORTHO-CLINICAL DIAGNOSTICS£295.7m
- BESPAK EUROPE LIMITED£256m
- SEQIRUS VACCINES LIMITED£254.2m
- IOVANCE BIOTHERAPEUTICS UK LTD£199.7m
Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant. The line on each bar marks the median.
Summary: ASTRAZENECA PLC
What kind of company is it?
ASTRAZENECA PLC is a public limited company registered with Companies House under company number 02723534. It was incorporated on 17 Jun 1992. Its status is active. The registered office is in Cambridge (CB2). Its nature of business (SIC 2007) is manufacture of basic pharmaceutical products (21100), manufacture of pharmaceutical preparations (21200), wholesale of pharmaceutical goods (46460), research and experimental development on biotechnology (72110).
How is the company doing financially?
The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files group accounts. Turnover was 58,739,000,000 USD. Profit for the year was 10,233,000,000 USD. Net assets were 48,719,000,000 USD, up 19.2% on the previous year. Cash at bank and in hand was 5,711,000,000 USD. Total assets were 114,074,000,000 USD and total liabilities 65,355,000,000 USD. Figures are available for 6 financial years (2020–2025).
How does it compare with similar companies?
Compared with 1,055 active companies whose first SIC code is 21100: It is older than 88% of them (median age 9.0 years).
Does it supply the public sector?
The company is named as a supplier in 3 public contract award notices from 3 public sector buyers since 2020. Contracts awarded to it alone have a combined published value of £90k. 1 of the awards is shared with other suppliers, typically framework agreements. It is recorded as the recipient of 14 central government grants worth £539.6k, mainly from Department for Business, Energy and Industrial Strategy.
What do public registers and reports show?
It has modern slavery statements on the government registry for 5 years.
Who runs and controls the company?
1 of 1 registered charges are outstanding.
When are its next filings due?
The next accounts are due by 30 Jun 2027. The next confirmation statement is due by 29 May 2027.
Dividends
from the accountsDividends paid in the financial year: 4,971,000,000 USD (49% of the profit for the year).
Filed accounts2020–2025
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Turnover | 37,417,000,000 | 44,351,000,000 | 45,811,000,000 | 54,073,000,000 | 58,739,000,000 |
| Profit for the year | 115,000,000 | 3,293,000,000 | 5,961,000,000 | 7,041,000,000 | 10,233,000,000 |
| Cash at bank and in hand | 6,329,000,000 | 6,166,000,000 | 5,840,000,000 | 5,488,000,000 | 5,711,000,000 |
| Total assets | 105,363,000,000 | 96,483,000,000 | 101,119,000,000 | 104,035,000,000 | 114,074,000,000 |
| Total liabilities | 66,076,000,000 | 59,425,000,000 | 61,953,000,000 | 63,164,000,000 | 65,355,000,000 |
| Net assets / total equity | 39,287,000,000 | 37,058,000,000 | 39,166,000,000 | 40,871,000,000 | 48,719,000,000 |
| Dividends paid | 3,856,000,000 | 4,364,000,000 | 4,481,000,000 | 4,629,000,000 | 4,971,000,000 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Public contracts
3 contractsASTRAZENECA PLC is named as a supplier in 3 public contract award notices from 3 public sector buyers since 2020. The 1 contract awarded to it alone with a published value add up to £90k. 1 award is shared with other suppliers and not counted in that total.
- Regional Business Services Organisation, Procurement and Logistics Service
- 1 contract · £90k
- Business Energy and Industrial Strategy
- 1 contract
- NHS England
- 1 contract
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18Regional Business Services Organisation, Procurement and Logistics Service · £90,000
- NHS Framework for the Midlands and East, Branded Medicines - Tranche BNHS England · shared by 37 suppliers, up to £228,156,862 in total
- Supply Agreement for AZD1222Business Energy and Industrial Strategy · £1
From contract award notices on Contracts Finder (since 2016) and Find a Tender (since 2021), published by the Cabinet Office under the Open Government Licence v3.0. Values are as published by the buyer and usually cover the whole contract term; the total leaves out awards shared between several suppliers, where the published figure is a ceiling for all of them, placeholder values and single figures of £1 billion or more. Contracts below the publication thresholds and those of devolved buyers that publish elsewhere are not included.
Government grants
14 grantsASTRAZENECA PLC is recorded as the recipient of 14 central government grants since 2020, together worth £539.6k.
- Department for Business, Energy and Industrial Strategy
- 6 grants · £270.9k
- Department for Science, Innovation and Technology
- 8 grants · £268.7k
- Maximising Efficiency of Liquid Phase Oligo Synthesis (MELOS)Department for Science, Innovation and Technology · £59,814 · UKRI - Innovate UK - Scheme
- Digital_LyoDepartment for Science, Innovation and Technology · £42,100 · UKRI - Innovate UK - Scheme
- 101057668 ETERNAL HORIZON-HLTH-2021-IND-07Department for Science, Innovation and Technology · £29,550 · UKRI - HEG - Scheme
- Translational Biopharmaceutics for Proteolysis Targeting Chimeras (PROTACs)Department for Business, Energy and Industrial Strategy · £11,697 · UKRI - Innovate UK - Scheme 22/23
- Cell-free glycoprotein synthesisDepartment for Business, Energy and Industrial Strategy · £28,934 · UKRI - Innovate UK - Scheme 22/23
Show 9 more
- SmartPSC (Smart Pharma Supply Chain): Application of digital technologies to integrate pharma manufacturing supply chain and enhance efficiency, productivity, flexibility, resilience, and sustainabilityDepartment for Business, Energy and Industrial Strategy · £177,047 · UKRI - ISCF - Scheme 22/23
- University of Strathclyde and AstraZeneca plc KTP 21_22 R2Department for Business, Energy and Industrial Strategy · £12,688 · UKRI - Innovate UK - Scheme 22/23
- University of Nottingham (The) and AstraZeneca plc KTP 21_22 R3Department for Business, Energy and Industrial Strategy · £11,423 · UKRI - Innovate UK - Scheme 22/23
- University of Nottingham (The) and AstraZeneca plc KTP 21_22 R3Department for Science, Innovation and Technology · £22,903 · UKRI - Innovate UK - Scheme
- University of Strathclyde and AstraZeneca plc KTP 21_22 R2Department for Science, Innovation and Technology · £24,017 · UKRI - Innovate UK - Scheme
- SmartPSC (Smart Pharma Supply Chain): Application of digital technologies to integrate pharma manufacturing supply chain and enhance efficiency, productivity, flexibility, resilience, and sustainabilityDepartment for Business, Energy and Industrial Strategy · £29,120 · UKRI - Innovate - Scheme 21/22
- SmartPSC (Smart Pharma Supply Chain): Application of digital technologies to integrate pharma manufacturing supply chain and enhance efficiency, productivity, flexibility, resilience, and sustainabilityDepartment for Science, Innovation and Technology · £75,300 · UKRI - ISCF - Scheme
- Translational Biopharmaceutics for Proteolysis Targeting Chimeras (PROTACs)Department for Science, Innovation and Technology · £8,442 · UKRI - Innovate UK - Scheme
- Cell-free glycoprotein synthesisDepartment for Science, Innovation and Technology · £6,538 · UKRI - Innovate UK - Scheme
From the Government Grants Register published by the Cabinet Office (financial years 2016/17 onwards, Open Government Licence v3.0). It covers grants from central government departments and their agencies where the register states the recipient's company number and the recipient name matches this company; grants from local authorities, lottery distributors and devolved governments are not included.
Statutory reporting
- 2026
- Statement · summary on GOV.UK · group statement
- 2025
- Statement · summary on GOV.UK · group statement
- 2024
- Statement · summary on GOV.UK · group statement
Earlier years (2)
- 2023
- Statement · summary on GOV.UK · group statement
- 2022
- Statement · summary on GOV.UK · group statement
Figures the company reported itself to the government's Check payment practices service, Gender pay gap service and Modern slavery statement registry (Open Government Licence v3.0). Only large companies and employers with 250 or more staff have to report, so most companies have nothing here.
History
7 events- Financial year 2025 endedAccounts: turnover 58.7bn USD, net assets 48.7bn USD
- Financial year 2024 endedAccounts: turnover 54.1bn USD, net assets 40.9bn USD
- Financial year 2023 endedAccounts: turnover 45.8bn USD, net assets 39.2bn USD
- Financial year 2022 endedAccounts: turnover 44.4bn USD, net assets 37.1bn USD
- Financial year 2021 endedAccounts: turnover 37.4bn USD, net assets 39.3bn USD
- Financial year 2020 endedAccounts: turnover 26.6bn USD, net assets 15.6bn USD
- Company incorporatedPublic limited company
Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current persons with significant control, and the end of each financial year with figures in the database. Former persons with significant control are not listed.